A Phase II, open-label, randomised study to assess the...

Investigational New Drugs 2011 / 10 Vol. 29; Iss. 5

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, Katalin Boer, Antoine Adenis, Pilar Escudero, Tae-You Kim, Gillian M. Pover, Clive D. Morris, Jean-Yves Douillard
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Language:
english
Pages:
8
DOI:
10.1007/s10637-010-9392-8
Date:
October, 2011
File:
PDF, 141 KB
english, 2011
Conversion to is in progress
Conversion to is failed